Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 20/20 | 0.93 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.93 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1689744 | 0.96 | LTB4R (1.00) | LTB4RCYP2C9LTB4R2 | |
| SCHEMBL1689839 | 0.92 | LTB4R (1.00) | LTB4RCYP2C9LTB4R2 | |
| SCHEMBL1689764 | 0.91 | LTB4R (1.00) | LTB4RCYP2C9LTB4R2 | |
| SCHEMBL1689831 | 0.91 | LTB4R (0.95) | LTB4RCYP2C9LTB4R2 | |
| SCHEMBL10165262 | 0.89 | LTB4R (0.74) | LTB4RCYP2C9LTB4R2 | |
| SCHEMBL1690010 | 0.88 | LTB4R (0.84) | LTB4RCYP2C9LTB4R2 | |
| SCHEMBL1690013 | 0.88 | LTB4R (1.00) | LTB4RCYP2C9LTB4R2 | |
| SCHEMBL1689747 | 0.87 | LTB4R (1.00) | LTB4RCYP2C9LTB4R2 | |
| SCHEMBL1689803 | 0.87 | LTB4R (0.92) | LTB4RCYP2C9LTB4R2 | |
| SCHEMBL1689717 | 0.87 | LTB4R (1.00) | LTB4RCYP2C9LTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093385-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093385-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093385-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2190808-A1 | LEUKOTRIENE B4 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009024492-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054466-A1 | Leukotriene B4 Inhibitors | DOMINIQUE ROMYR | 2009-02-26 | — | — | US | disclosed |
| US-20090054466-A1 | Leukotriene B4 Inhibitors | DOMINIQUE ROMYR | 2009-02-26 | — | — | US | disclosed |
| US-20090054466-A1 | Leukotriene B4 Inhibitors | DOMINIQUE ROMYR | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054466-A1 | Leukotriene B4 Inhibitors | LTB4R2, LTB4R, LTC4S | LTB4R 2/4885CYP2C9 279/4885LTB4R2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.